Long-term Outcome of Schilder Disease Treated With Interferon-β.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 31662417.
- Also identified by DOI 10.1542/peds.2019-0505.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Schilder disease, also termed diffuse myelinoclastic sclerosis, is characterized by a large demyelinating lesion involving 1 or both sides of the centrum semiovale of the cerebral hemispheres. It often presents with tumorlike features and poses a diagnostic challenge. Schilder disease can be monophasic or relapsing, and disease-modifying therapy for the latter scenario is largely empirical. Here, we report a 14-year-old girl with relapsing Schilder disease within 1 year after disease onset. She has been followed-up for nearly 10 years and remains in sustained remission ever since interferon-β therapy was prescribed after the second attack. In this case study, it is suggested that interferon-β may induce long-term remission in relapsing Schilder disease and is therefore worth considering in this regard.
Medical subject headings
- Brain
- Diffuse Cerebral Sclerosis of Schilder
- Immunologic Factors
- Interferon beta-1a